acquired
Stage
3
Investors
About
Candid Therapeutics develops treatments targeting autoimmune diseases and has been acquired by UCB Pharma to advance therapeutic programs in this field.
Explore Candid Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.